Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 2.43
OREX's Cash to Debt is ranked lower than
54% of the 763 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.71 vs. OREX: 2.43 )
Ranked among companies with meaningful Cash to Debt only.
OREX' s Cash to Debt Range Over the Past 10 Years
Min: 2.21  Med: 24.35 Max: No Debt
Current: 2.43
Equity to Asset 0.14
OREX's Equity to Asset is ranked lower than
96% of the 701 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. OREX: 0.14 )
Ranked among companies with meaningful Equity to Asset only.
OREX' s Equity to Asset Range Over the Past 10 Years
Min: -0.73  Med: 0.35 Max: 0.78
Current: 0.14
-0.73
0.78
F-Score: 3
Z-Score: -3.19
M-Score: 1.19
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -245.53
OREX's Operating margin (%) is ranked lower than
92% of the 708 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.77 vs. OREX: -245.53 )
Ranked among companies with meaningful Operating margin (%) only.
OREX' s Operating margin (%) Range Over the Past 10 Years
Min: -107754.55  Med: -3403.74 Max: -54.99
Current: -245.53
-107754.55
-54.99
Net-margin (%) -280.83
OREX's Net-margin (%) is ranked lower than
92% of the 711 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.28 vs. OREX: -280.83 )
Ranked among companies with meaningful Net-margin (%) only.
OREX' s Net-margin (%) Range Over the Past 10 Years
Min: -105954.55  Med: -3422.74 Max: -67.59
Current: -280.83
-105954.55
-67.59
ROE (%) -312.25
OREX's ROE (%) is ranked lower than
99% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.97 vs. OREX: -312.25 )
Ranked among companies with meaningful ROE (%) only.
OREX' s ROE (%) Range Over the Past 10 Years
Min: -246.53  Med: -116.89 Max: -42.04
Current: -312.25
-246.53
-42.04
ROA (%) -31.42
OREX's ROA (%) is ranked lower than
86% of the 765 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.77 vs. OREX: -31.42 )
Ranked among companies with meaningful ROA (%) only.
OREX' s ROA (%) Range Over the Past 10 Years
Min: -101.77  Med: -58.00 Max: -19.09
Current: -31.42
-101.77
-19.09
ROC (Joel Greenblatt) (%) -6431.56
OREX's ROC (Joel Greenblatt) (%) is ranked lower than
96% of the 757 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.44 vs. OREX: -6431.56 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OREX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -34518.01  Med: -5974.94 Max: -3874.08
Current: -6431.56
-34518.01
-3874.08
Revenue Growth (3Y)(%) 57.40
OREX's Revenue Growth (3Y)(%) is ranked higher than
96% of the 594 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.00 vs. OREX: 57.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
OREX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 57.40 Max: 211.9
Current: 57.4
0
211.9
EBITDA Growth (3Y)(%) -29.00
OREX's EBITDA Growth (3Y)(%) is ranked lower than
90% of the 545 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.70 vs. OREX: -29.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
OREX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -49.8  Med: -24.40 Max: -8
Current: -29
-49.8
-8
EPS Growth (3Y)(%) -25.60
OREX's EPS Growth (3Y)(%) is ranked lower than
85% of the 501 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.20 vs. OREX: -25.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
OREX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -55.5  Med: -23.30 Max: -8.6
Current: -25.6
-55.5
-8.6
» OREX's 10-Y Financials

Financials (Next Earnings Date: 2016-05-04)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

OREX Guru Trades in Q1 2015

Steven Cohen 2,048,300 sh (New)
Paul Tudor Jones 37,027 sh (New)
John Burbank 51,980 sh (New)
» More
Q2 2015

OREX Guru Trades in Q2 2015

Jim Simons 420,400 sh (New)
John Burbank Sold Out
Steven Cohen Sold Out
Paul Tudor Jones 14,200 sh (-61.65%)
» More
Q3 2015

OREX Guru Trades in Q3 2015

Seth Klarman 821,363 sh (New)
Jim Simons 2,780,376 sh (+561.36%)
Paul Tudor Jones 11,163 sh (-21.39%)
» More
Q4 2015

OREX Guru Trades in Q4 2015

Paul Tudor Jones 101,438 sh (+808.70%)
Seth Klarman 2,268,399 sh (+176.17%)
Jim Simons 1,766,200 sh (-36.48%)
» More
» Details

Insider Trades

Latest Guru Trades with OREX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Orexigen Therapeutics Inc

Seth Klarman Buys Pharmaceutical Company's Shares to Fund International Drug Launch Investment will help the company expand its hit weight-loss drug
True to form, Seth Klarman (Trades, Portfolio) purchased a stake in a pharmaceutical company with a sinking stock but a new blockbuster drug ready to push out the door. Read more...

Ratios

vs
industry
vs
history
P/B 1.92
OREX's P/B is ranked higher than
64% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.82 vs. OREX: 1.92 )
Ranked among companies with meaningful P/B only.
OREX' s P/B Range Over the Past 10 Years
Min: 0.98  Med: 5.60 Max: 1627.5
Current: 1.92
0.98
1627.5
P/S 2.30
OREX's P/S is ranked higher than
55% of the 691 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.76 vs. OREX: 2.30 )
Ranked among companies with meaningful P/S only.
OREX' s P/S Range Over the Past 10 Years
Min: 2.3  Med: 159.09 Max: 2985
Current: 2.3
2.3
2985
EV-to-EBIT 1.04
OREX's EV-to-EBIT is ranked higher than
98% of the 525 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.51 vs. OREX: 1.04 )
Ranked among companies with meaningful EV-to-EBIT only.
OREX' s EV-to-EBIT Range Over the Past 10 Years
Min: -39.6  Med: -3.50 Max: 2.5
Current: 1.04
-39.6
2.5
EV-to-EBITDA 1.04
OREX's EV-to-EBITDA is ranked higher than
98% of the 552 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.66 vs. OREX: 1.04 )
Ranked among companies with meaningful EV-to-EBITDA only.
OREX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -39.9  Med: -3.50 Max: 2.6
Current: 1.04
-39.9
2.6
Current Ratio 7.25
OREX's Current Ratio is ranked higher than
86% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. OREX: 7.25 )
Ranked among companies with meaningful Current Ratio only.
OREX' s Current Ratio Range Over the Past 10 Years
Min: 3.3  Med: 6.78 Max: 19.3
Current: 7.25
3.3
19.3
Quick Ratio 6.92
OREX's Quick Ratio is ranked higher than
87% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. OREX: 6.92 )
Ranked among companies with meaningful Quick Ratio only.
OREX' s Quick Ratio Range Over the Past 10 Years
Min: 3.3  Med: 6.77 Max: 19.3
Current: 6.92
3.3
19.3
Days Sales Outstanding 101.89
OREX's Days Sales Outstanding is ranked lower than
69% of the 610 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.16 vs. OREX: 101.89 )
Ranked among companies with meaningful Days Sales Outstanding only.
OREX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 8.2  Med: 16.90 Max: 101.89
Current: 101.89
8.2
101.89

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.29
OREX's Price/Net Cash is ranked higher than
67% of the 209 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.97 vs. OREX: 6.29 )
Ranked among companies with meaningful Price/Net Cash only.
OREX' s Price/Net Cash Range Over the Past 10 Years
Min: 1.01  Med: 6.51 Max: 50.5
Current: 6.29
1.01
50.5
Price/Net Current Asset Value 2.10
OREX's Price/Net Current Asset Value is ranked higher than
88% of the 428 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.81 vs. OREX: 2.10 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
OREX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1  Med: 6.25 Max: 35.65
Current: 2.1
1
35.65
Price/Tangible Book 1.92
OREX's Price/Tangible Book is ranked higher than
71% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.50 vs. OREX: 1.92 )
Ranked among companies with meaningful Price/Tangible Book only.
OREX' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.99  Med: 5.93 Max: 33.48
Current: 1.92
0.99
33.48
Price/Median PS Value 0.02
OREX's Price/Median PS Value is ranked higher than
100% of the 637 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.16 vs. OREX: 0.02 )
Ranked among companies with meaningful Price/Median PS Value only.
OREX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.06  Med: 0.98 Max: 11.63
Current: 0.02
0.06
11.63
Earnings Yield (Greenblatt) (%) 96.20
OREX's Earnings Yield (Greenblatt) (%) is ranked higher than
99% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. OREX: 96.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
OREX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 39.6  Med: 111.40 Max: 2099.6
Current: 96.2
39.6
2099.6

More Statistics

Revenue(Mil) $24
EPS $ -0.53
Beta2.85
Short Percentage of Float15.85%
52-Week Range $0.39 - 6.96
Shares Outstanding(Mil)145.57

Analyst Estimate

Dec16 Dec17
Revenue(Mil) 46 121
EPS($) -0.40 -0.22
EPS without NRI($) -0.40 -0.22

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:XKRX:053950, NAS:CPIX, HKSE:00932, ROCO:6553, BOM:524164, HKSE:01889 » details
Traded in other countries:JXS.Germany,
Orexigen Therapeutics Inc was incorporated in Delaware in September 2002. Company is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of obesity. Its product candidates are NB32, which has completed Phase III clinical trials and which is currently being studied in a cardiovascular outcomes trial, and Empatic, which has completed Phase II clinical trials. Both NB32 and Empatic regulate appetite and energy expenditure through central nervous system activity. NB32 is a fixed dose combination of bupropion and naltrexone. Company develops its product candidates for large markets traditionally served by primary care physicians. In order to effectively promote NB32 to these physicians, in September 2010, it entered into a collaboration agreement with Takeda to develop and commercialize NB32 in the United States, Canada and Mexico. It maintains an aggressive intellectual property strategy, which includes patent and trademark filings in multiple jurisdictions including the United States and other commercially significant markets. It relies on a combination of in-licensed patent rights, its own patent rights, trademarks, trade secrets and know-how to protect NB32 and Empatic. Its products used in clinical trials have been produced by outside contractors under its supervision. Company competes with AstraZeneca, Athersys, Inc., Bristol-Myers Squibb, Norgine BV, Novo Nordisk A/S, among others.
» More Articles for OREX

Headlines

Articles On GuruFocus.com
Seth Klarman’s Largest New Buys and Adds Feb 15 2016 
Value Investing in BioPharma Nov 18 2015 
Seth Klarman Buys Pharmaceutical Company's Shares to Fund Drug Launch Oct 12 2015 
Oxford Industries (OXM) Solid Growth Metrics, Orexigen Therapeutics (OREX) European Anti-Obesity App Mar 27 2015 
Orexigen Therapeutics' Bright Future Mar 03 2015 
Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 
Weekly CEO Sells Highlight: Orexigen Therapeutics Inc, Gas Natural Inc, The Middleby Corporation, an Jul 15 2012 
Weekly CEO Sells Highlight: Gas Natural Inc, Encore Bancshares Inc, Staples Inc, and Orexigen Therap Jul 08 2012 
Arena Facing Increased Pressure from Peers Apr 23 2012 
Arena Could Dip If Lorcaserin Fails Again Apr 22 2012 

More From Other Websites
OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... May 04 2016
Orexigen Therapeutics Inc Earnings Call scheduled for 5:00 pm ET today May 04 2016
Orexigen reports 1Q loss May 04 2016
Orexigen reports 1Q loss May 04 2016
Orexigen Therapeutics Reports Business and Financial Results for the First Quarter Ended March 31,... May 04 2016
4:03 pm Orexigen Therapeutics beats by $0.01, misses on revs May 04 2016
Orexigen Therapeutics Reports Business and Financial Results for the First Quarter Ended March 31,... May 04 2016
Q1 2016 Orexigen Therapeutics Inc Earnings Release - After Market Close May 04 2016
Orexigen Therapeutics to Speak at the Bank of America Merrill Lynch 2016 Health Care Conference May 03 2016
Orexigen Therapeutics to Speak at the Bank of America Merrill Lynch 2016 Health Care Conference May 03 2016
Orexigen Expands Commercial Leadership Team with Appointment of Healthcare Industry Veteran Brian... May 03 2016
Orexigen Expands Commercial Leadership Team with Appointment of Healthcare Industry Veteran Brian... May 03 2016
Orexigen Announces South Korean Approval of Contrave® (naltrexone HCI and bupropion HCI... May 02 2016
Orexigen Announces South Korean Approval of Contrave® (naltrexone HCI and bupropion HCI... May 02 2016
Orexigen Announces Upcoming Presentations at XIII International Congress on Obesity hosted by the... Apr 28 2016
Penny Stocks To Watch: Four Top Small Cap Stocks on Monday April 25 Apr 25 2016
Orexigen Therapeutics Expands Commercial Capabilities with Appointment of Beth Eastland, Vice... Apr 25 2016
Orexigen Therapeutics Expands Commercial Capabilities with Appointment of Beth Eastland, Vice... Apr 25 2016
The Zacks Analyst Blog Highlights: Medivation, Synta, AbbVie, Gilead and Orexigen Apr 21 2016
Orexigen Therapeutics to Provide Business Update and Discuss First Quarter 2016 Financial Results on... Apr 20 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK